A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
2010 ◽
Vol 12
(7)
◽
pp. 503-508
◽
Keyword(s):
Phase Ii
◽
2009 ◽
Vol 27
(5)
◽
pp. 572